Status:

UNKNOWN

Liver Fibrosis and Gut Microbiota in Patients With Psoriasis Vulgaris and Rheumatoid Arthritis on Methotrexate

Lead Sponsor:

The University of Hong Kong

Conditions:

Psoriasis Vulgaris

Rheumatoid Arthritis

Eligibility:

All Genders

18-85 years

Brief Summary

While methotrexate (MTX) remains a treatment of choice for patients with rheumatoid arthritis (RA), psoriasis (PsO) and psoriatic arthritis (PsA), long-term MTX use has been shown to be associated wit...

Eligibility Criteria

Inclusion

  • Age between 18 to 85 years
  • Have regular follow up in Dermatology/ Rheumatology clinics of Queen Mary Hospital
  • Diagnosed with PsO/PsA or RA
  • Chinese ethnicity

Exclusion

  • Age below 18 years or above 85 years
  • Known decompensated cirrhosis
  • Pregnancy or breastfeeding
  • Unstable medical illness or active infection
  • Unable to provide written consent
  • Unable to adhere to the protocol
  • Unable to read and/or write Chinese language
  • On anticoagulant/ antiplatelet treatment
  • Abnormal platelet count \<150
  • Known disease/condition with prolonged INR/bleeding tendency

Key Trial Info

Start Date :

August 13 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 11 2022

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT04493762

Start Date

August 13 2020

End Date

December 11 2022

Last Update

July 30 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Liver Fibrosis and Gut Microbiota in Patients With Psoriasis Vulgaris and Rheumatoid Arthritis on Methotrexate | DecenTrialz